BioChem Pharma's genomics investment

In lieu of investments in individual genomics companies, BioChem Pharma Inc. has invested C$30 million (US$21.9 million) in a C$100 million (US$73 million) venture capital fund that will focus on early stage genomics technologies. BCHXF's indirect wholly owned

Read the full 382 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE